3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Colorectal Neoplasms
7
Neoplasms
4
Multiple Myeloma
4
Hematologic Neoplasms
3
Glioma
3
Thyroid Carcinoma, Anaplastic
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Colonic Neoplasms
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Nonseminomatous germ cell tumor
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Melanoma
1
Interventions
Irinotecan
4
Gemcitabine
4
130-nm albumin-bound paclitaxel
4
napabucasin
3
Cyclophosphamide
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
selpercatinib
2
pembrolizumab
2
cobimetinib
2
Sunitinib
2
Sorafenib
2
Pemetrexed
2
Paclitaxel
2
Leucovorin
2
Fluorouracil
2
Drug Therapy
2
Chemoradiotherapy
2
Cetuximab
2
Aspirin
2
Ascorbic Acid
2
trametinib
1
repotrectinib
1
pralsetinib
1
osimertinib
1
lutetium Lu 177 dotatate
1
linifanib
1
guadecitabine
1
golotimod
1
genexol-PM
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
dabrafenib
×
Gastrointestinal
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled